




Official Journal of the European Paediatric Neurology Society



## Review article

## The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy

Florian Heinen<sup>a,\*</sup>, Kaat Desloovere<sup>b</sup>, A. Sebastian Schroeder<sup>a</sup>, Steffen Berweck<sup>c</sup>, Ingo Borggraefe<sup>a</sup>, Anya van Campenhout<sup>d</sup>, Guro L. Andersen<sup>e</sup>, Resa Aydin<sup>f</sup>, Jules G. Becher<sup>g</sup>, Günther Bernert<sup>h</sup>, Ignacio Martinez Caballero<sup>i</sup>, Lucinda Carr<sup>j</sup>, Emmanuelle Chaleat Valayer<sup>k</sup>, Maria Teresa Desiato<sup>l</sup>, Charlie Fairhurst<sup>m</sup>, Paul Filipetti<sup>n</sup>, Ralph-Ingo Hassink<sup>o</sup>, Ulf Hustedt<sup>p</sup>, Marek Jozwiak<sup>q</sup>, Serdar Ibrahim Kocer<sup>r</sup>, Elisabeth Kolanowski<sup>s</sup>, Ingeborg Krägeloh-Mann<sup>t</sup>, Şehim Kutlay<sup>u</sup>, Helena Mäenpää<sup>v</sup>, Volker Mall<sup>w</sup>, Paul McArthur<sup>x</sup>, Edith Morel<sup>k</sup>, Antigone Papavassiliou<sup>y</sup>, Ignacio Pascual-Pascual<sup>z</sup>, Søren Anker Pedersen<sup>aa</sup>, Frank S Plasschaert<sup>bb</sup>, Irene van der Ploeg<sup>cc</sup>, Olivier Remy-Neris<sup>dd</sup>, Anne Renders<sup>ee</sup>, Guiseppe Di Rosa<sup>ff</sup>, Maja Steinlin<sup>gg</sup>, Kristina Tedroff<sup>hh</sup>, Joan Vidal Valls<sup>ii</sup>, Elke Viehweger<sup>jj</sup>, Guy Molenaers<sup>d</sup>

<sup>a</sup> Department of Paediatric Neurology and Developmental Medicine, Dr. von Hauner's Children's Hospital, University of Munich, Lindwurmstr. 4, 80337 Munich, Germany

<sup>b</sup> Department of Rehabilitation Sciences KUL, University Hospital of Pellenberg, Belgium

<sup>c</sup> Specialist Centre for Paediatric Neurology, Epilepsy Centre for Children and Adolescents, Krankenhausstraße 20, 83569 Vogtareuth, Germany

<sup>d</sup> Department of Orthopaedics KUL, University Hospital of Pellenberg, Belgium

<sup>e</sup> Habilitation Center, SiV HF, Postboks 2168, 3103 Tønsberg, Norway

<sup>f</sup> Department of Physical Medicine and Rehabilitation, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

<sup>g</sup> Department of Rehabilitation Medicine, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands

<sup>h</sup> Gottfried von Preyer'sches Kinderspital der Stadt Wien, Austria

<sup>i</sup> Department of Pediatric Orthopaedics, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Spain

<sup>j</sup> Department of Neurology, Great Ormond Street Hospital for Children, London, UK

<sup>k</sup> Centre médico-chirurgical et de réadaptation des Massues, Lyon, France

<sup>l</sup> Department of Neurophysiopathology, ASL RMC, S. Eugenio Hospital, Rome, Italy

<sup>m</sup> Guy's and St Thomas' Hospitals, London, UK

<sup>n</sup> Motion Lab Analysis. Rehazenter, 1, Rue André Vesale, L-2674, Luxembourg

<sup>o</sup> Zentrum für Entwicklungsförderung und pädiatrische Neurorehabilitation“ (Z.E.N.) der Stiftung Wildermeth, Kloosweg 22, CH-2502 Biel, Switzerland

<sup>p</sup> Department of Social Paediatrics, Hospital of the City of Frankfurt, Gotenstrasse 6–8, 65929 Frankfurt, Germany

<sup>q</sup> Department of Pediatric Orthopedics and Traumatology, K Marcinkowski Medical University, 28 Czerwca 1956 r str. No 135/147, 61-545 Poznan, Poland

<sup>r</sup> Centra Med Physique Rééducation, Rééducation Neurologique, Départementale 96, Coubert, France

<sup>s</sup> Centre de Rééducation Fonctionnelle Marc Sautetlet-APF, Villeneuve d'Ascq, France

<sup>t</sup> Department of Paediatric Neurology and Developmental Neurology, Children's Hospital, University of Tuebingen, Germany

<sup>u</sup> Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Ankara University, Ankara, Turkey

\* Corresponding author. Fax: +49 89 5160 7745.

<sup>v</sup> Rehabilitation Unit of Neurology, University Hospital for children and adolescents in Helsinki, Lastenlinnantie2, PL 280, 00029 Helsinki, Finland

<sup>w</sup> Department of Pediatrics and Adolescent Medicine, Division of Neuropediatrics and Muscular Disorders, University Hospital Freiburg, Freiburg, Germany

<sup>x</sup> Department of Congenital Hand and Upper Limb Surgery, Alder Hey Children's Hospital, Liverpool, UK

<sup>y</sup> Department of Neurology, Pendeli Children's Hospital, Athens, Greece

<sup>z</sup> Department of Child Neurology, Hospital Infantil La Paz, Universidad Autónoma de Madrid, Spain

<sup>aa</sup> Department of Pediatrics 460 University Hospital Hvidovre., 2650 Hvidovre, Denmark

<sup>bb</sup> Department Orthopaedic Surgery, University Hospital Gent, De Pintelaan 185, 9000 Gent, Belgium

<sup>cc</sup> University Hospitals Coventry and Warwickshire, Office ABR 10065, Ward 16, Clifford Bridge Road, Coventry, CV2 2DX, West Midlands, UK

<sup>dd</sup> Centre hospitalier universitaire de Brest, service de medecine physique et readaptation 2 Avenue Foch, Brest, France

<sup>ee</sup> Cliniques Universitaires Saint-Luc, 10 avenue Hippocrate 1200 Brussels, Belgium

<sup>ff</sup> Ospedale Pediatrico Bambino Gesù, Roma, Italy

<sup>gg</sup> Inselspital Bern, Freiburgstrasse 4, Bern 3010, Switzerland

<sup>hh</sup> Neuropediatric Unit, Astrid Lindgren Children's Hospital, Department of Woman and Child Health, Karolinska Institutet and Stockholm Brain Institute, Sweden

<sup>ii</sup> Centre Pilot Arcàngel Sant Gabriel, ASPACE Barcelona C/Tres Pins s/n, 08038 Barcelona, Spain

<sup>jj</sup> Hôpital Timone Enfants, Service Orthopédie Pédiatrique, Pôle 13 Chirurgie Infantile, 264 Rue Saint Pierre, et Faculté de Médecine, Université de la Méditerranée., Boulevard Jean Moulin, Marseille, France

## ARTICLE INFO

### Article history:

Received 28 July 2009

Received in revised form

15 September 2009

Accepted 17 September 2009

### Keywords:

Botulinum toxin

Cerebral palsy

## ABSTRACT

An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). A problem-orientated approach was used focussing on both published and practice-based evidence. In part I of the consensus the authors have tabulated the supporting evidence to produce a concise but comprehensive information base, pooling data and experience from 36 institutions in 9 European countries which involves more than 10,000 patients and over 45,000 treatment sessions during a period of more than 280 treatment years. In part II of the consensus the Gross Motor Function Measure (GMFM) and Gross Motor Function Classification System (GMFCS) based Motor Development Curves have been expanded to provide a graphical framework on how to treat the motor disorders in children with CP. This graph is named "Cp<sup>Graph</sup> Treatment Modalities – Gross Motor Function" and is intended to facilitate communication between parents, therapists and medical doctors concerning (1) achievable motor function, (2) realistic goal-setting and (3) treatment perspectives for children with CP. The updated European consensus 2009 summarises the current understanding regarding an integrated, multidisciplinary treatment approach using Botulinum toxin for the treatment of children with CP.

© 2009 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

## Contents

1.	Part I: update of the table .....	47
1.1.	Legend to the consensus table .....	47
1.2.	Essentials of 2009 .....	47
2.	Sections 1–10 .....	47
2.1.	Cerebral palsy (section 1) .....	47
2.2.	Medico-legal and medico-economical aspects (section 2) .....	54
2.3.	Botulinum toxin and integrated therapy (section 3) .....	54
2.4.	Botulinum toxin and common indications (section 4) .....	54
2.5.	Dosage and dose modifiers of Botulinum toxin therapy (section 5) .....	54
2.6.	Safety of Botulinum toxin (section 6) .....	55
2.7.	Botulinum toxin therapy and procedures (section 7) .....	55
2.8.	Assessment and evaluation of treatment with BoNT in children with CP (section 8) .....	55

2.9. Botulinum toxin therapy adherence (section 9) .....	56
2.10. CP is a research challenge (section 10) .....	56
3. Part II: introduction of the CP <sup>Graph</sup> Treatment Modalities – Gross Motor Function .....	56
3.1. The need and chance for visualisation .....	56
Conflicts of interest .....	59
Acknowledgements .....	59
References .....	59

## 1. Part I: update of the table

### 1.1. Legend to the consensus table

The Consensus update 2009 presents a conceptual framework for best practice in the use of Botulinum toxin (BoNT) in children with cerebral palsy (CP). Since the first European consensus table on Botulinum toxin for children with CP in 2006<sup>1</sup> basic research, clinical trials, new treatment strategies and safety regards have evolved in the expanding field of CP management. The aim of this updated, annotated, and tabulated evidence report (Table 1) is to incorporate the recent advances in knowledge into all sections of the earlier consensus table. A comprehensive literature search in PubMed (including MEDLINE, NLM Gateway, PreMEDLINE, HealthSTAR, as well as publisher supplied citations) was performed as described in the first European consensus<sup>1</sup> including literature from June 2006 until June 2009. Previously cited literature was only removed if there was more accurate literature published on a topic or level of evidence could be increased with new literature.

Besides literature enhancement, the updated European consensus table is based on data from an extended number of 36 European treatment centres. The authors were able to draw upon the combined experience of more than 280 treatment years, more than 10,000 treated patients, and more than 45,000 treatment sessions to condense the knowledge in the consensus table.

### 1.2. Essentials of 2009

- (1) Changing the Paradigm from “Botulinum toxin” to “Activity is supported by Botulinum toxin”: Activity is supported by BoNT and *vice versa*: due to its mechanism of action, BoNT only reduces muscle tone in the active, non fibrotic, “non-contracted” part of the muscle. However, by reducing tone in the muscle it allows stretch to be applied, which is in itself a stimulus for muscle growth. Activity, which means function, (e.g. dorsiflexion of the foot during the gait cycle) is dependant on the agonistic activity of a particular muscle (in this case tibialis anterior muscle). BoNT supports the agonist’s activity by reducing muscle tone and regulatory circuits of the antagonist (here triceps surae muscle). To improve function, activity, participation and development of a child with CP additional therapies have to be included (see also Sections 3 and 4).
- (2) “Safety and publicity”: BoNT reflects all the benefits and controversies of modern medicine: strong and ongoing medical success as well as a fashion-driven presence on

“how to design a perfect body”, oversimplified enthusiasm, mass media presence, and headline catching criticism. Due to the wide number of indications Pharm Allergan (Preparation Botox<sup>®</sup> and Vistabel<sup>®</sup>), Ipsen Pharma (Preparation Dysport<sup>®</sup>), Merz Pharmaceuticals (Preparation Xeomin<sup>®</sup>) and Solstice Neuroscience (Preparation Neurobloc/Myobloc<sup>®</sup>) have had to document the possibility of severe systemic side effects in a “red hand letter” in Europe in June 2007 (download at: The German Federal Institute for Drugs and Medical Devices (BfArM <http://www.bfarm.de/>), followed by an FDA statement in February 2008 (<http://www.fda.gov>), and a statement produced by Swissmedic (<http://www.swissmedic.ch>) in June 2008. In September 2008 the German BfArM published the conclusive statement that currently “there is no evidence showing a causal connection” between the fatal outcome of 5 patients and their prior treatment with Botulinum toxin.<sup>2</sup> A follow-up statement of the FDA was published in May 2009 stating that FDA has notified the manufacturers of licensed Botulinum toxin products of the need to strengthen warnings in product labelling and that manufacturers have to develop and implement a Risk Evaluation and Mitigation Strategy (REMS) to provide more information regarding the risk for distant spread of Botulinum toxin effects after local injection in the future.<sup>3</sup> It rests in the hand of the treating physician to be up to date on the ongoing safety and labelling discussions using the above mentioned health agencies and their internet domains. Additional information can be accessed at the European Medicines Agency (EMA: <http://www.emea.europa.eu/>).

The members of the consensus group are strongly committed to emphasise the ongoing need for a careful, unbiased and transparent documentation of any adverse events in the children with CP who are treated with BoNT, ideally stratified by GMFCS levels (see also Section 2.6).

## 2. Sections 1–10

### 2.1. Cerebral palsy (section 1)

CP is the most common cause of spastic movement disorders in children.<sup>4,5</sup> Epidemiologic data has shown that with the advanced care in neonatal medicine the incidence and severity of CP in premature children of very low birth weight in Europe<sup>6</sup> and northern America<sup>7</sup> is decreasing. Our

(Continued on page 10)

**Table 1 – Updated European consensus table on the use of Botulinum toxin for children with cerebral palsy**

Section	Key areas – updated consensus	Key literature – selected clinical studies and reviews
1 Cerebral palsy: epidemiology, etiology phenomenology	<p>Epidemiology</p> <ul style="list-style-type: none"> <li>- CP is the most prevalent cause for motor disorders in childhood</li> <li>- The socio-economic impact of CP is high</li> <li>- The prevalence is 2–3 per 1000 live births</li> <li>- The prevalence increases up to 100 per 1000 live births in extreme pre-maturity</li> </ul> <p>Etiology</p> <p>Time of lesion – lesion pattern</p> <ul style="list-style-type: none"> <li>- 1st + 2nd trimester – maldevelopments</li> <li>- early 3rd trimester – periventricular leucomalacia (PVL), intraventricular hemorrhage (IVH)</li> <li>- late 3rd trimester – cortical-subcortical and deep grey matter lesions</li> </ul> <p>The motor disorder in CP involves supra-spinal motor centres, cortico-spinal tracts, segmental spinal circuits and the musculo-skeletal system.</p> <p>Phenomenology</p> <ul style="list-style-type: none"> <li>- Type (spastic, dyskinetic or ataxic CP)</li> <li>- Distribution (bilateral or unilateral)</li> <li>- Severity (GMFCS Level I–V)</li> <li>- Comorbidity (e.g. epilepsy, mental retardation, sensory impairment etc.)</li> </ul>	<p>Clinical studies</p> <ul style="list-style-type: none"> <li>• Epidemiological studies on CP<sup>6,7,84–87</sup></li> </ul> <p>Reviews</p> <ul style="list-style-type: none"> <li>• Actual classification of CP<sup>88–92</sup></li> <li>• Classification of cerebral lesions in CP acc. to MRI<sup>11,93</sup></li> <li>• Epidemiology<sup>94</sup></li> <li>• Definitions of dystonia, rigidity and spasticity in children<sup>95</sup></li> <li>• Pathophysiology on paediatric motor disorders<sup>96</sup></li> <li>• Musculo-skeletal aspects of CP<sup>97,98</sup></li> </ul>
2 Medico-legal and medico-economical aspects	<p>Medico-legal aspects</p> <ul style="list-style-type: none"> <li>- Users should be familiar with the guidelines for registration of BoNT applicable in their countries.</li> <li>- Comprehensively explain the proposed therapy to parents and caregivers and obtain written consent.</li> <li>- Meticulously document treatment details including evaluation of functional outcome.</li> <li>- Enhance pharmaco-vigilance by rigorously reporting all adverse events</li> </ul>	<p>Clinical studies</p> <ul style="list-style-type: none"> <li>• Socio-economic impact of CP<sup>99–102</sup></li> <li>• Off-label use in paediatrics<sup>103</sup></li> <li>• Off-label therapy in Germany<sup>104</sup></li> </ul> <p>Reviews</p> <ul style="list-style-type: none"> <li>• Minimal acceptable standards of healthcare<sup>105</sup></li> <li>• BoNT is elemental part of spasticity treatment<sup>106</sup></li> <li>• Statement of the Society for Neuropediatrics<sup>107</sup></li> <li>• Social outcomes of children with CP<sup>108</sup></li> </ul>
3 Botulinum toxin, integrated therapy (see also: Fig. 1: CP <sup>Graph</sup> Treatment Modalities – Gross Motor Function)	<p>Therapeutic options should consider all dimensions of the International Classification of Functioning Disability and Health (ICF of the WHO):</p> <ul style="list-style-type: none"> <li>- Body structure</li> <li>- Body function</li> <li>- Activity</li> <li>- Participation</li> <li>- Environmental factors</li> </ul> <p>Integrative aspect</p> <p>BoNT can be combined with all other treatment modalities, e.g.</p> <ul style="list-style-type: none"> <li>- BoNT + all modalities of functional therapy: Physiotherapy, OT, speech therapy, constraint-induced movement therapy (CIMT), robotic assisted therapy, etc.</li> <li>- BoNT + orthoses, casting, splinting</li> <li>- BoNT + intrathecal baclofen or other pharmacotherapy</li> <li>- BoNT + surgical intervention</li> </ul>	<p>Clinical Studies</p> <ul style="list-style-type: none"> <li>• BoNT combined with other treatments ([II],<sup>21</sup> [II],<sup>77</sup> [II],<sup>109</sup> [II],<sup>110</sup> [II],<sup>111</sup> [II],<sup>112</sup> [II],<sup>69</sup> [II],<sup>113</sup> [II],<sup>114</sup> [II],<sup>115</sup> [II],<sup>116</sup> [II],<sup>117</sup> [II],<sup>118</sup> [II],<sup>119</sup> [II],<sup>120</sup> [II],<sup>121</sup> [IV]<sup>122</sup>)</li> <li>• Evidence based treatment in CP ([V]<sup>123</sup>)</li> </ul>

#### 4 Botulinum toxin and common indications

##### Key therapists (in alphabetical order)

- Developmental Paediatrician
- Functional therapist (physiotherapy, occupational therapy etc.)
- Orthopaedic surgeon
- Orthotist
- Paediatric neurologist
- Rehabilitation specialist

##### General considerations

- A developmental disorder needs an adaptive approach to cope with the changing patterns that occur during the course of development.
- During the time of the most rapid motor development, the reversibility of any treatment option is of value.
- (The reduction of the M-response as a measure for the paralysing effect of BoNT seems to be effected more readily in dystonic muscles compared to spastic muscles.)

Therapy goals should be established by consent prior to therapy, adapted to:

- GMFCS or MACS (see also Section 3, 8, and the CP<sup>Graph</sup> Treatment Modalities – Gross Motor Function)
  - Focal, multifocal or multi-level approach
  - Functional relevance may include improved mobility (function, activity, participation), ease of care, prevention of deformity or pain
- The therapy goals should address specific clinical problems and patterns in paediatric lower and upper extremity spasticity (the following terminology is used in the cited studies but is not seen as “up to date” by the consensus group. The corresponding SCPE terminology is displayed in parentheses:
- Spastic quadriplegia (bilateral spastic CP)
  - Spastic pes equinus (unilateral or bilateral spastic CP)
  - Crouch-gait, hip flexion (bilateral spastic CP)
  - Adductor spasticity (bilateral spastic CP)
  - Upper limb flexor deformity (unilateral or bilateral spastic CP)
  - Amelioration of pain (unilateral, bilateral spastic, or dyskinetic CP)

##### Reviews

- WHO/ICF/CP<sup>68,124</sup>
- Therapeutic interventions in CP<sup>125,126</sup>
- Pharmacotherapy of spasticity<sup>125–127</sup>
- BoNT & physical therapy<sup>128–130</sup>
- BoNT & occupational therapy<sup>131</sup>
- BoNT & casting<sup>132</sup>
- CIMT in CP<sup>133</sup>
- Existing consensus<sup>1,98,134</sup>
- Minimal acceptable standards for healthcare<sup>105</sup>
- Effectiveness of therapy after BoNT<sup>24</sup>
- Effectiveness of casting, physical therapy interventions and orthoses in CP<sup>135,136</sup>

##### Clinical studies

- Spastic quadriplegia ([IV]<sup>137</sup>)
- Spastic pes equinus ([I],<sup>138</sup> [II],<sup>139</sup> [III],<sup>140</sup> [II],<sup>141</sup> [III],<sup>142</sup> [III],<sup>77</sup> [III],<sup>143</sup> [IV],<sup>144</sup> [IV]<sup>145</sup>)
- Crouch-gait/flexed-knee gait ([III],<sup>119</sup> [IV]<sup>146</sup>)
- Adductor spasticity ([II],<sup>114</sup> [III]<sup>147</sup>)
- Upper limb flexor deformity ([III],<sup>148</sup> [II],<sup>149</sup> [III],<sup>21</sup> [II],<sup>117</sup> [III],<sup>120</sup> [II],<sup>116</sup> [II],<sup>121</sup> [III],<sup>150</sup> [IV]<sup>136</sup>)
- Analgesic effects of BoNT therapy ([III],<sup>110</sup> [IV]<sup>151</sup>)
- Quantification of the M-response in dystonic and spastic muscles ([I],<sup>138</sup> [IV]<sup>152</sup>)

##### Reviews

- Rehabilitation of children with CP<sup>153</sup>
- Clinical value of BoNT<sup>154</sup>
- Family-centred service for children with CP<sup>155</sup>
- On CP and BoNT<sup>156,157</sup>
- Cochrane review: BoNT as an adjunct to treatment in the management of the upper limb<sup>158</sup>
- Cochrane review: treatment of lower limb spasticity in CP<sup>159</sup>

(continued on next page)

Table 1 (continued)

Section	Key areas – updated consensus	Key literature – selected clinical studies and reviews																								
5 Dosage and dose modifiers of Botulinum toxin therapy <sup>a</sup>	<p>Preparations</p> <p>In children with CP the available preparations can not be exchanged with a fixed ratio due to different pharmacokinetic and pharmacodynamic characteristics (no conversion factors).</p> <p>Physicians need to be aware of national/local licensing restrictions</p> <p>Cautions</p> <ul style="list-style-type: none"> <li>- dose per muscle should not be increased</li> <li>- dose per site should not be increased</li> <li>- number of muscles treated should follow the clinical need</li> <li>- undertreatment should be avoided</li> <li>- carefully calculation of total dose, see dose modifiers below</li> </ul> <p>Dose ranges [U = Units; kg bw = kilogram body weight]<sup>a</sup></p> <p>BoNT Serotype A</p> <ul style="list-style-type: none"> <li>- Preparation BOTOX<sup>®</sup> <table border="0" data-bbox="634 608 991 683"> <tr> <td>range [U/kg bw]</td> <td>1–20 (–25)</td> </tr> <tr> <td>max total dose [U]</td> <td>400 (–600)</td> </tr> <tr> <td>range max dose/site [U]</td> <td>10–50</td> </tr> </table> </li> <li>- Preparation Dysport<sup>®</sup> <table border="0" data-bbox="634 715 991 790"> <tr> <td>range [U/kg bw]</td> <td>1–20 (–25)</td> </tr> <tr> <td>max total dose [U]</td> <td>500–1000</td> </tr> <tr> <td>range max dose/site [U]</td> <td>50–250</td> </tr> </table> </li> <li>- Preparation Xeomin<sup>®</sup> (adult studies suggest dosage equivalence with Botox<sup>®</sup>,<sup>160, 161</sup> but for children this needs to be confirmed) <table border="0" data-bbox="634 847 1087 922"> <tr> <td>range [U/kg bw]</td> <td>not established yet</td> </tr> <tr> <td>max total dose [U]</td> <td>not established yet</td> </tr> <tr> <td>max dose/site [U]</td> <td>not established yet</td> </tr> </table> </li> </ul> <p>BoNT Serotype B</p> <ul style="list-style-type: none"> <li>- Preparation Neurobloc<sup>®</sup> (mainly used as second line preparation in adult neurology in case of secondary non-response to BoNT/A) <table border="0" data-bbox="634 1007 1055 1082"> <tr> <td>range [U/kg bw]</td> <td>not established</td> </tr> <tr> <td>max total dose [U]</td> <td>not established</td> </tr> <tr> <td>max dose/site [U]</td> <td>not established</td> </tr> </table> </li> </ul> <p>Dose modifiers</p> <ul style="list-style-type: none"> <li>- Severity of CP according to GMFCS</li> <li>- Accompanying diagnoses (e.g. dysphagia, aspiration pneumonia, hypopnea)</li> <li>- Predominant type of movement disorder (spastic versus dyskinetic),</li> <li>- Activity of the injected muscle (dynamic versus fibrotic compounds of the muscle)</li> <li>- Muscle bulk size</li> <li>- Nutritional status, body mass index</li> <li>- Knowledge about the distribution of motor endplates in the injected muscle</li> <li>- Experience from previous BoNT injections</li> </ul> <p>Dilution can be adapted to body region and muscle size (e.g. forearm: lower dilution, lower leg: higher dilution).</p>	range [U/kg bw]	1–20 (–25)	max total dose [U]	400 (–600)	range max dose/site [U]	10–50	range [U/kg bw]	1–20 (–25)	max total dose [U]	500–1000	range max dose/site [U]	50–250	range [U/kg bw]	not established yet	max total dose [U]	not established yet	max dose/site [U]	not established yet	range [U/kg bw]	not established	max total dose [U]	not established	max dose/site [U]	not established	<p>Pharmacology</p> <ul style="list-style-type: none"> <li>• Mechanism of action of BoNT Serotype A<sup>162–165</sup> and Serotype B<sup>166</sup></li> </ul> <p>Clinical studies</p> <ul style="list-style-type: none"> <li>• Preparation Botox<sup>®</sup> <ul style="list-style-type: none"> <li>• 4 U Botox<sup>®</sup>/kg body weight (pes equinus) ([I]<sup>138</sup>)</li> <li>• 20–30 U Botox<sup>®</sup>/kg body weight (multi-level, multi-muscle approach) ([IV],<sup>33</sup> [IV]<sup>167</sup>)</li> <li>• Dilution of 1–4 ml/Vial preparation Botox<sup>®</sup> ([III]<sup>41</sup>)</li> </ul> </li> <li>• Preparation Dysport<sup>®</sup> <ul style="list-style-type: none"> <li>• 15–30 U Dysport<sup>®</sup>/kg body weight (pes equinus, adductor spasticity) ([II],<sup>77</sup> [II],<sup>114</sup> [I]<sup>168</sup>)</li> <li>• Dilution of 1–5 ml/Vial preparation Dysport<sup>®</sup> ([III]<sup>169</sup>)</li> </ul> </li> <li>• Preparation Neurobloc<sup>®</sup> <ul style="list-style-type: none"> <li>• Up to 400 U Neurobloc<sup>®</sup>/kg body weight in a small pilot study ([IV],<sup>170</sup> [IV]<sup>171</sup>)</li> </ul> </li> <li>• Low versus high dosage (upper and lower limb) ([I],<sup>168</sup> [III],<sup>150</sup> [II],<sup>172</sup> [III]<sup>52</sup>)</li> <li>• Dosage in multi-level treatment ([V],<sup>34</sup> [II],<sup>69</sup> [V],<sup>33</sup> [IV]<sup>51</sup>)</li> <li>• Dose modifiers<sup>39</sup></li> </ul> <p>Reviews</p> <ul style="list-style-type: none"> <li>• Pharmacology of Botulinum Toxins<sup>173</sup></li> <li>• Physiological effects of BoNT in spasticity<sup>174</sup></li> <li>• Dose ranges: <ul style="list-style-type: none"> <li>• Up to 16 U Botox<sup>®</sup>/kg bw<sup>39</sup></li> <li>• Up to 23 U Botox<sup>®</sup>/kg bw<sup>20</sup></li> <li>• Up to 25 U Dysport<sup>®</sup>/kg bw<sup>175</sup></li> </ul> </li> </ul> <p>Internet sources</p> <ul style="list-style-type: none"> <li>• BoNT dosing tables: <a href="http://www.mdvu.org/">http://www.mdvu.org/</a> (Login required)</li> </ul>
range [U/kg bw]	1–20 (–25)																									
max total dose [U]	400 (–600)																									
range max dose/site [U]	10–50																									
range [U/kg bw]	1–20 (–25)																									
max total dose [U]	500–1000																									
range max dose/site [U]	50–250																									
range [U/kg bw]	not established yet																									
max total dose [U]	not established yet																									
max dose/site [U]	not established yet																									
range [U/kg bw]	not established																									
max total dose [U]	not established																									
max dose/site [U]	not established																									

## 6 Safety of Botulinum toxin

Three types of adverse events:

## (1) Focal adverse events

- Local weakening beyond the therapy goal can occur when muscle size, dosing guidelines and dilution guidelines are not respected or when inadequate localisation techniques are applied.
- Distant adverse events (e.g. bladder dysfunction) can be observed when dosing and dilution guidelines are neglected or inadequate localisation techniques are applied.

## (2) Generalised adverse events

- Generalised weakness has been observed and reported and can occur when preparation specific dosage and dilution guidelines are not respected.

## (3) Procedural adverse events

- Haematoma (rare when small 27–30 gauge needles are used).
  - No reports on local infections following BoNT injections have been published or reported by the users of BoNT.
  - procedural complications due to analgo-sedation or general anaesthesia
- Specific risks of mortality and morbidity according to GMFCS need to be addressed in future evaluations <sup>54</sup>

## 7 Botulinum toxin therapy and procedures

Administration by an experienced team in a setting appropriate for children

The therapy setting has to be adapted according to the patients needs adequate analgesia (in combination with sedation if necessary)

- Technique of injection (sonography, electrical stimulation, EMG)

## 8 Assessment and evaluation of treatment with BoNT in children with CP

Documentation and evaluation should use validated methods (according to ICF/WHO).

Clinical studies safety

- Report on the safety and occurrence of adverse events after repeated injections (preparation Dysport<sup>®</sup>)<sup>176</sup>
- Report on adverse events in severe CP after repeated injections (preparation BOTOX<sup>®</sup>) ([V]<sup>54</sup>)
- Report on safety of treatment and frequency of adverse events in large cohort (preparation BOTOX<sup>®</sup>) ([IV]<sup>33</sup>)
- Report on safety of treatment with high-dose BoNT/A (BOTOX<sup>®</sup>) ([IV],<sup>51</sup> [IV],<sup>50</sup> [IV],<sup>52</sup> [IV]<sup>53</sup>)
- Safety profile of BoNT/A treatment in children (preparation Dysport<sup>®</sup>)<sup>42</sup>
- Report on dysphagia after BoNT/B ([V]<sup>177</sup>)
- Secondary non-response after repeated injections (BoNT/B) ([V]<sup>178</sup>)
- Accuracy is relevant for the safety of treatment ([III]<sup>21</sup>)
- Case-report on systemic effect of BoNT ([V]<sup>54</sup>)
- Report on the safety and adverse effects of BoNT/A, both BOTOX<sup>®</sup> and Dysport<sup>®</sup>, in children below 2 year of age ([IV]<sup>47</sup>)

Reviews

- Meta-analysis on safety, incl. data from adults and children<sup>43</sup>
- Safety of long-term use<sup>44</sup>
- Safety of BoNT-A<sup>49</sup>

Clinical studies procedure

- Accuracy of palpation/electrical stimulation<sup>59,66</sup>
- BoNT injection using sonography<sup>60,67</sup>
- Sonography-guided psoas injection<sup>61,65</sup>
- Repeated injections without general anaesthetic<sup>179</sup>
- N<sub>2</sub>O in paediatric patients<sup>56,57,180,181</sup>

Reviews

- EMG, pro/contra<sup>182,183</sup>
- Management of pain and anxiety<sup>184</sup>
- Methodology of sonography-guided injection<sup>62,64</sup>

Validity and reliability

- Joint Range of Motion<sup>185,186</sup>
- Ashworth Scale<sup>187,188</sup>
- Tardieu Scale<sup>188,189</sup>
- QEK, Deep-tendon reflexes, Clonus<sup>139</sup>
- GMFM<sup>14,15,190,191</sup>
- GAS<sup>192–194</sup>
- Video documentation,<sup>195</sup> Edinburgh Visual GAIT,<sup>196,197</sup> Physician Rating Scale, Observational Gait Scale<sup>198</sup>
- PEDI,<sup>199</sup> BFMP,<sup>200</sup> MACS<sup>201,202</sup>
- AHA: Assisting Hand Assessment,<sup>203</sup> Melbourne Assessment<sup>204–206</sup>
- Longitudinal health outcome,<sup>207</sup> Health-related quality of life<sup>b208–210</sup>

(continued on next page)

Table 1 (continued)

Section	Key areas – updated consensus	Key literature – selected clinical studies and reviews
	<p>Body structure/function e.g.:</p> <ul style="list-style-type: none"> <li>- Range of motion (ROM)</li> <li>- (modified) Ashworth Scale [(M)AS]</li> <li>- Tardieu Scale</li> <li>- Quantitative Electromyographic Kinesiology (QEK)</li> <li>- Deep-tendon reflexes</li> <li>- Clonus</li> <li>- 3D gait analysis</li> <li>- Video documentation</li> <li>- Goal Attainment Scale (GAS)</li> </ul> <p>Activity/participation e.g.:</p> <ul style="list-style-type: none"> <li>- 3D gait analysis</li> <li>- 3D kinematics in upper limb</li> <li>- Gross Motor Function Measure (GMFM)</li> <li>- Manual Ability Classification System (MACS)</li> <li>- WeeFIM™ (Functional Independence Measure)</li> <li>- Paediatric Evaluation of Disability Inventory (PEDI)</li> <li>- Canadian Occupational Performance Measure (COPM)</li> <li>- Child Health Questionnaire (CHQ)</li> <li>- Quality of Upper Extremity Skills Test (QUEST)</li> <li>- Melbourne Assessment of unilateral upper limb function</li> <li>- Bimanual Fine Motor Function (BFMF)</li> <li>- AHA (Assisting Hand Assessment)</li> <li>- Physician Rating Scale, Observational Gait Scale</li> <li>- Edinburgh Visual Gait Analysis Interval Testing Scale</li> <li>- Energy expenditure measures</li> <li>- Goal Attainment Scale (GAS)</li> <li>- Visual Analogue Scale (VAS)</li> <li>Caregiver Priorities &amp; Child Health Index of Life with Disabilities (CPCHILD®) questionnaire<sup>b</sup></li> </ul>	<p>Clinical Studies containing BoNT intervention</p> <ul style="list-style-type: none"> <li>• ICF in CP ([III]<sup>124</sup>)</li> <li>• Ashworth Scale ([III]<sup>187</sup>), Tardieu Scale<sup>189</sup></li> <li>• SMS, QEK, Deep-tendon reflexes, clonus ([II]<sup>139</sup>)</li> <li>• GMFM ([II],<sup>139</sup> [II]<sup>119</sup>)</li> <li>• GAS ([IV],<sup>211</sup> [IV],<sup>212</sup> [II]<sup>21</sup>)</li> <li>• Energy cost ([II]<sup>118</sup>)</li> <li>• Video documentation, Edinburgh Visual GAIT ([II]<sup>118</sup>), Observational Gait Scale ([I]<sup>138</sup>), PEDI ([II],<sup>120</sup> [II]<sup>213</sup>), COPM ([II],<sup>21</sup> [II]<sup>120</sup>)</li> <li>• Melbourne Assessment ([II]<sup>120</sup>), QUEST ([II],<sup>21</sup> [II]<sup>120</sup>)</li> <li>• 3D gait analysis ([II],<sup>69</sup> [IV],<sup>214</sup> [III],<sup>70</sup> [IV]<sup>71</sup>)</li> <li>• 3D kinematics in upper limb ([V]<sup>215</sup>)</li> <li>• VAS ([IV]<sup>216</sup>)</li> </ul> <p>Reviews</p> <ul style="list-style-type: none"> <li>• ICF approach<sup>68</sup></li> <li>• Evaluating therapy<sup>217–219,133</sup></li> <li>• Measures for muscles and joint in lower limb<sup>220</sup></li> <li>• Systematic literature review of assessment measures<sup>221</sup></li> <li>• Review of spasticity assessment measures<sup>222,188</sup></li> <li>• Review of measurements of activity level<sup>223</sup></li> </ul>



<p>9 Botulinum toxin therapy adherence</p>	<p>Continuation</p> <ul style="list-style-type: none"> <li>• Improved function</li> <li>• Improved balance/posture</li> <li>• Improved pain and comfort</li> <li>• Crucial factors for treatment success: <ul style="list-style-type: none"> <li>- Number of treatments (although repeated treatments are successful, the largest functional improvement usually occurs after the first treatment)</li> <li>- dosages (different dosages may produce different levels of response)</li> <li>- Follow-up care (combination with functional therapy, orthotic management, casting) seems crucial for a good result</li> <li>- Age (younger children seem to respond better)</li> <li>- Functional level (can influence a positive outcome)</li> <li>- Individualised treatment approach with respect to muscle selection</li> </ul> </li> </ul> <p>Discontinuation</p> <ul style="list-style-type: none"> <li>• Continued benefit without further injections</li> <li>• No significant gain or unacceptable side effects</li> <li>• Secondary non-response</li> <li>• Fibrosis</li> <li>• Neutralizing antibodies against BoNT</li> <li>• Continuation to orthopaedic treatment, intrathecal baclofen, or others</li> </ul>	<p>Clinical studies</p> <ul style="list-style-type: none"> <li>• Antibody screening in children with CP (mouse protection bioassay) ([III]<sup>78</sup>)</li> <li>• Antibody screening in children with CP (mouse hemidiaphragm assay,<sup>80,178</sup> [V])</li> <li>• Rate of antibody formation for BoNT (preparation BOTOX<sup>®</sup>) in adults<sup>81</sup></li> <li>• Long-term use ([IV],<sup>224</sup> [II],<sup>213</sup> [II]<sup>225</sup>)</li> <li>• Why children discontinue treatment<sup>79</sup></li> </ul>
<p>10 Research challenge CP</p>	<p>(1) Evaluation of injection techniques and follow-up:</p> <ul style="list-style-type: none"> <li>- Effect of BoNT within the muscle</li> <li>- dilution, distribution, spreading within the muscle</li> <li>- location of injection sites</li> <li>- motor endplate targeting</li> </ul> <p>(2) Evaluation of patient and treatment characteristics of high and low responders.</p> <p>(3) The effects of BoNT in combination with a goal directed therapy and follow-up care.</p>	<p>(1) Follow up: Muscle biopsy substantiates longterm MRI alterations one year after a single dose of Botulinum toxin injected into the lateral gastrocnemius muscle of two healthy volunteers.<sup>226</sup></p> <p>(3) Activity focused and goal directed therapy for children with cerebral palsy.<sup>227</sup></p>

Level of evidence in parentheses behind clinical trials: I–V according to AACPD Methodology to Develop Systematic Reviews of Treatment Interventions (Revision 1.2) 2008 Version<sup>83</sup>.

I = systematic review of randomized controlled trials (RCTs), Large RCTs (with narrow confidence intervals;  $n > 100$ ).

II = smaller RCTs (with wider confidence intervals;  $n < 100$ ), Systematic reviews of cohort studies, 'Outcomes research' (very large ecological studies).

III = cohort studies (must have concurrent control group), systematic reviews of case–control studies.

IV = case series, cohort study without concurrent control group, case–control study.

V = expert opinion, case study or report; bench research, expert opinion based on theory or physiologic research, common sense/anecdotes.

Citations are sorted chronologically, alphabetically and by level of evidence, if possible.

a Dose rests in the hand of treating physician (read carefully Sections 2, 4, 6).

b CPCHILD Questionnaire to be downloaded at <http://www.sickkids.ca/Research/CPCHILD-Questionnaire/CPCHILD-Project/CPChild-questionnaire/index.html>.

understanding of the etiology, or at least the pathogenesis, of the disease has been greatly advanced by the development of Magnetic Resonance Imaging techniques, which allow the identification of the underlying structural changes in the brain<sup>8,9</sup> and gives information on topography and the extent and potential timing of the causative lesion.<sup>10,11</sup> Although the cerebral lesion in CP is viewed as caused by a single event, CP has to be understood as a developmental disorder described over time as an individual develops. The development of the European consensus on CP definition and classification<sup>12</sup> and its illustration by a video-based manual (the Reference and Training Manual of the SCPE) provides a practical basis for a unified approach with respect to diagnosis.<sup>13</sup> A whole body approach to classification (and reclassification) is facilitated by the use of the Gross Motor Function Classification System (GMFCS), which describes both disease severity and course.<sup>14,15</sup>

Reclassification of a child is recommended during every appointment, especially when the child is under the age of four years. Classification according to GMFCS may also be used for decision-making concerning which treatment intervention is appropriate over the course of time (see also Section 3). The GMFCS classification system is a useful tool for hip surveillance programs as was shown by a Swedish group in 2007.<sup>16</sup> Classifications by GMFCS and ‘limb distribution’ or by GMFCS and ‘type of motor impairment’ are significantly correlated.<sup>17</sup> However, an analysis of function (GMFCS) by impairment (limb distribution) indicated that the limb distribution did not add prognostic value over GMFCS, although classification of CP by impairment level seems useful for clinical and epidemiological purposes.<sup>17,18</sup> These recommendations are in line with a report on the definition and classification of cerebral palsy as published by an international consensus group.<sup>19</sup>

## 2.2. Medico-legal and medico-economical aspects (section 2)

BoNT treatment of children with CP is often performed under unlicensed conditions, using dosages and body segments or muscles which are not supported by the relevant licensing bodies. However, the off-label use of medications is accepted and common practice in many paediatric fields and will continue until there is a significant increase in research directed at children. Typically the licences for BoNT treatment show a great variety between countries (in Europe and all other continents) and are restricted to specific preparations, specific indications and dose limitations. Licensing does not reflect the clinical need, especially for children with CP. Individualised variations in BoNT dosage, BoNT dilution, clinical indication(s) and the muscle group(s) treated represent appropriate, although unlicensed, use where such treatment is in line with clinical experience.<sup>20</sup> A strong level of pharmacovigilance is required due to the broad spectrum of indications ranging from single muscle injections in children with e.g. unilateral CP, GMFCS Level I versus multi-level injections in severely affected children with bilateral CP, GMFCS Levels III–IV (-V) suffering from multiple additional impairments. In order to assess adverse events sufficiently, a new system of pharmacovigilance documentation in the field of off-label use was addressed by the NIH to be developed for the future. In conclusion, careful decision-making on

dosage, dilution and injection control rests in the hands of the treating physician and has to be adapted to the individual patient (see Sections 2.5 and 2.6).

## 2.3. Botulinum toxin and integrated therapy (section 3)

The use of BoNT in children with CP represents a major therapeutic intervention but should never be considered as a stand-alone treatment. The treatment approach to the spastic movement disorders associated with CP must include the whole range of conservative and surgical strategies and regularly requires an interdisciplinary multi-modal team approach. Recent developments in the field show that the advanced use of BoNT i.e. combined with different conservative (or non-conservative) treatment options, has the potential to achieve functional benefits for children with CP.<sup>21–23</sup> However, there is insufficient evidence to either support or refute the use of these interventions before or after BoNT injections.<sup>24</sup>

A combination of therapy procedures is common in daily practice, but addressing this by research is far from being easy. Robotic assisted therapy can serve as an intervention model where activity parameters can be measured during therapy intervention.<sup>25–30</sup> This may allow a better understanding about the correlation of effect of dosing to activity and whether this has any effect on participation.

## 2.4. Botulinum toxin and common indications (section 4)

Spastic movement disorders in children with CP are a result of the involvement of the brain, central motor pathways, spinal circuits and musculo-skeletal system. With ongoing child motor development spastic movement disorders develop into distinctive motor patterns, which need to be recognised and should be used to guide treatment. Starting in the 1990s an increasing number of “focal” indications emerged such as *pes equinus*, *pes equinovarus*, knee and hip flexion spasticity, adductor spasticity, and spasticity of the upper extremity (e.g. finger flexion, wrist flexion, ulnar deviation, elbow flexion, and shoulder adduction). In a non-focal condition such as CP, a number of muscle groups may need to be targeted.<sup>31,32</sup> This has led to the development of a multi-muscle, multi-level treatment approach, in which a number of overactive muscle groups are treated with BoNT to achieve an improvement of limb motion and posture.<sup>33,34</sup> The use of classifications, e.g. for sagittal gait patterns<sup>31</sup> may facilitate the development of more standardized pattern-guided treatment approaches.

## 2.5. Dosage and dose modifiers of Botulinum toxin therapy (section 5)

To date two preparations of BoNT Serotype A – Botox® (Allergan Inc.) and Dysport® (Ipsen Ltd.) – have demonstrated focal efficacy and functional gains for children with CP. A third BoNT/A preparation (Xeomin®, Merz Pharma, Germany) was introduced to the market in 2005 with anecdotal reports on beneficial effect in children with neuro-paediatric indications.<sup>35</sup> All Botulinum toxin products are distinct concerning their molecular structure and manufacturing process and methods used for determining

biological activity are different.<sup>36–38</sup> For children with CP, these pharmacological differences have significant implications for clinical use. Individual dosages must be calculated independently for each BoNT preparation and fixed dose-conversion factors are not applicable in the treatment of spasticity in children with CP.<sup>3,33,39</sup>

Dosage calculation for each preparation is based on: (1) total units per treatment session, (2) total units per kg body weight per session, (3) units per muscle, (4) units per injection site, (5) units per kg body weight per muscle (U/kg/muscle). It has to be respected that the term “Unit” represents a different biologic potency for each BoNT preparation.

Additional dose modifiers which have to be considered when planning the injection protocol may be: severity of CP according to GMFCS, accompanying diagnoses (e.g. dysphagia, aspiration, breathing problems), predominance of movement disorder (spasticity, dystonia), activity of the injected muscle, muscle size, dynamic versus fibrotic muscle, knowledge about the distribution of motor endplates in the injected muscle, and experience from previous BoNT injections. Dilution will depend on body region and muscle size (e.g. forearm versus upper leg). In animal models higher dilutions showed greater dissemination,<sup>40</sup> but clinical evidence to support this information is missing.<sup>41</sup>

## 2.6. Safety of Botulinum toxin (section 6)

BoNT therapy has been widely used for over 20 years during which time it has proved to be a safe treatment option.<sup>33,42–49</sup> In general, the occurrence and severity of CP adverse events are rare. With the development of the multi-level treatment strategy over the last years it has become apparent that an adequate focal treatment effect can only be achieved when the injected dose/muscle remains the same.<sup>34</sup> Consequently, the total dose/session increases with the number of treated muscles, but this needs to be differentiated from “overdosing” a single muscle. Adverse events can be differentiated into focal (local, distant), generalised and procedural adverse events. With the development of the multi-level treatment strategy a dose dependency of adverse events is discussed<sup>50</sup> although this observation could not be supported by other groups.<sup>51–53</sup>

Heightened interest concerning safety has occurred since severe adverse events (deterioration in respiratory and oromotor function) were reported in a child with CP after BoNT treatment (see introduction).<sup>54</sup> With the report of severe adverse events to national health institutions a so-called “red hand letter” was published in Germany by the German Federal Institute for Drugs and Medical Devices (BfArM, <http://www.bfarm.de/>) on June 1, 2007.<sup>55</sup> In the United States the national non-profit “Public Citizen” interest Organisation followed with a petition in January 2008, insisting on transparency of Botulinum toxin treatment in the USA (<http://www.citizen.org/publications/release>). Following this petition a warning was issued by health institutions from several countries: the Food and Drug Administration (FDA, <http://www.fda.gov>) in the USA, Health Canada (<http://www.hc-sc.gc.ca>) and by the Swiss Agency for Therapeutic Products ([www.swissmedic.ch](http://www.swissmedic.ch)) in Europe 2008. In September 2008 the BfArM published a conclusive statement that

currently “there is no evidence showing a causal connection” between the fatal outcome of five reported patients in Germany and their prior treatment with Botulinum toxin.<sup>2</sup> The ongoing discussion concerning safety and licensing of BoNT needs to be followed carefully by each treating physician using the websites of the above mentioned health institutions. It is important to emphasise that it remains the responsibility of the treating physician to “check and balance” dosing, dose modifying effects and procedural risks (as general anaesthesia) for each child on an individual basis keeping in mind the treatment goal(s), national and institutional rules. The GMFCS helps to anticipate severity-related co-morbidities which should be taken into account in every BoNT treatment session. According to the Surveillance of Cerebral Palsy in Europe the GMFCS was distributed at Level I in 32%, Level II in 29%, Level III in 8%, Level IV in 15%, and Level V in 16%. Learning disability was present in 40%, epilepsy in 33%, and severe visual impairment in 19% of the children. More severe GMFCS levels correlated with larger proportions of accompanying impairments<sup>18</sup> and a greater incidence of brain stem pathology and cranial nerve dysfunction, that needs to be assessed prior to BoNT treatment. The potential additional risk for the different subgroups of GMFCS evolving from treatment with BoNT remains to be clarified and is currently under investigation in different centres worldwide.

## 2.7. Botulinum toxin therapy and procedures (section 7)

In children with CP, pain management is an important issue. Procedural pain such as BoNT injections requires appropriate, effective analgesia, especially because BoNT therapy requires repeated multiple, painful, but elective injections. Therefore, appropriate, effective analgesia and as the case arises in combination with sedation is a fundamental and an ethical necessity. The optimal regimen will vary between individuals and will be influenced by the age of the child, the GMFCS, the number of muscles to be treated and the institutional setting and resources.<sup>56,57</sup> The procedural pain management includes pharmacological as well as non-pharmacological techniques and already starts prior to the procedure. Useful comprehensive guidelines can be found at the webpage of The Royal Australasian College of Physicians Sydney (<http://www.racp.edu.au/page/health-policy-and-advocacy/paediatrics-and-child-health>).<sup>58</sup> Children should receive injections delivered using an accurate localisation technique.<sup>21,59</sup> Classical neurophysiological localisation methods (EMG, electrical stimulation) have recently been fine-tuned and amended by sonography which allows precise identification of any target muscle using readily available, non-invasive equipment.<sup>60–67</sup>

## 2.8. Assessment and evaluation of treatment with BoNT in children with CP (section 8)

The development of new CP assessment tools has been stimulated by the therapeutic possibilities offered by BoNT therapy. Purpose-built classification tools and standardized clinical assessments enable people to speak the same language and to evaluate interventions using consistent and

valid instruments, matched to the dimensions of the international classification of functioning, disability and health (ICF).<sup>68</sup> The cited literature in the table represents an excerpt of the assessment and evaluation tools for treatment with BoNT in children with CP. A large number of studies in literature report about the effect of BoNT predominantly only on the level of body structure and function (e.g. Ashworth and/or, Tardieu scores and Range of Motion). Gait analysis data provide important information for delineating the problems of children with CP.<sup>23,69–71</sup> With respect to study design, attempts are necessary to further improve the quality to allow meta-analysis of studies. The following issues are important: (1) Stratification of patients according to age, Gross Motor Function/Manual abilities and type/characteristic of movement disorder, (2) randomization centrally organized, independent from the physician doing the intervention, (3) Blinded rating of treatment effects, e.g. through blinded video analysis in conjunction with appropriate outcome measures, (4) standardization of co-interventions, (5) intention-to-treat analysis of drop-out patients. Qualitative research which aims to make sense of, or interpret experiences of individuals,<sup>72–75</sup> and aids in evaluating the complexity of evidence-based clinical decisions<sup>76</sup> will also be valuable.

### 2.9. Botulinum toxin therapy adherence (section 9)

In a randomized controlled clinical trial 48% of children treated with BoNT showed clinical improvement of initial foot contact using a video gait analysis compared to 17% of placebo treated children.<sup>77</sup> A multicenter open label clinical trial enrolling 207 children with CP showed an improvement of dynamic gait pattern on the Physician Rating Scale in 46% of patients (86/185) at first follow-up. BoNT injections (4 U/Kg, Botox<sup>®</sup>) were given approximately every 3 months. The mean duration of BoNT/A exposure was 1.46 years per patient and the response was maintained in 41–58% of patients for 2 years.<sup>78</sup> Initial reports on long-term adherence show that, while about 75% of patients achieve their treatment goals following the initial injection sessions, a considerable number discontinue therapy for various reasons.<sup>79</sup> Further research will need to delineate and quantify what factors determine continuation or discontinuation of therapy.

Non-responsiveness to BoNT can occur as a result of (i) insufficient injection accuracy, (ii) predominant muscle fibrosis or (iii) the formation of antibodies. In children undergoing BoNT treatment in the 1990s up to 30% were reported to develop antibodies.<sup>80</sup> Although higher dosages per session have recently been administered to children with CP, secondary non-response due to the presence of antibodies is no longer experienced as a clinically relevant problem due to the use of reformulated BoNT.<sup>23,33</sup> This is in line with reports that have demonstrated reduced antigenicity of the reformulated preparation in adults with cervical dystonia.<sup>81</sup> In conclusion antibody formation does not seem to affect clinical decision and any “new” BoNT formulations that are introduced would have to prove their superiority to established preparations.<sup>82</sup>

### 2.10. CP is a research challenge (section 10)

A sample of three exemplary research topics addressing some clinical aspects of BoNT treatment with the multi-modal treatment concept are named to stimulate future work.

## 3. Part II: introduction of the CP<sup>Graph</sup> treatment modalities – gross motor function

### 3.1. The need and chance for visualisation

A further development of this updated consensus table is the introduction of an integrative treatment graph for children with bilateral spastic cerebral palsy (CP<sup>Graph</sup> Treatment Modalities – Gross Motor Function (Fig. 1)).

This graph was presented as a draft and discussed at the consensus meeting and has been adapted on the basis of vivid discussions. It represents the likely path of motor development in a group of children with bilateral spastic CP based on the GMFM/GMFCS-based Motor Development Curves.<sup>228</sup> It describes the principles of common treatment options which can be considered in an interdisciplinary setting. The goal is to provide parents and caretakers, physicians and therapists with a means to plan treatments and interventions within the multidisciplinary treatment approach and to help answer questions concerning: What? When? How much? How long?

At the same time the limitations of a graphical conclusion have to be considered: The graph is not designed to show a predictable and detailed course of development for the individual child and it does not serve as a fixed protocol for the interdisciplinary treatment team.


The basal (green) curve represents all functional therapies. It forms the foundation to which all other therapies can be added on demand. These other therapies are coded with other colours (bright green = orthoses/aids, yellow = oral medication, orange = Botulinum toxin, red = intrathecal baclofen, blue = orthopaedic surgery):

*Functional therapies (basal, green line):* support of motor development in children with CP is the continuous principle of care. Besides adaptive support of motor development, negative alterations can be uncovered and addressed as they appear by e.g. short term intensification of treatment blocks.<sup>135,229–231</sup>

*Orthoses/aids (bright green line):* goal and therapeutic benefit need to be defined ideally in conjunction with the orthotist, paediatric neurologist, and paediatric orthopaedic. Improvement of function in daily activity, but also prevention of structural deformities are the two most important therapeutic goals.<sup>132,232</sup>

*Ambulatory aids* are essential for participation in daily activities. *Oral medication (yellow line):* oral, anti-spasticity medication aims to generally reduce muscle tone in children with CP. Due to frequent habituation to applied dosages, treatment often is limited to short- or medium-term benefit. Generalised systemic side effects frequently limit the application of adequate dosages for a sufficient tone reduction.<sup>233,234</sup>

*Botulinum toxin (orange line):* its indication has been applied to all grades of severity in children with CP (GMFCS I–V). As a focal treatment for a non-focal disease it ranges from focal



## INDICATION, PRINCIPLE & LIMITATION



1: European Medicines Agency (EMA: [www.wmwa.europe.eu](http://www.wmwa.europe.eu)), The German Federal Institute for Drugs and Medical Devices (BfArM: <http://www.bfarm.de>), Swiss Agency for Therapeutic Products (Swissmedic: [www.swissmedic.ch](http://www.swissmedic.ch)), Food and Drug Administration (FDA: [www.fda.gov](http://www.fda.gov)).

**Fig. 1 – CP<sup>Graph</sup> treatment modalities – gross motor function.**

to multi-level injections. Distant action and systemic action of substance may occur when dose recommendations and dose modifiers are not regarded.<sup>45,70</sup>

*Intrathecal baclofen (red line):* the indication for ITB has been established for GMFCS levels IV and V, rarely III. The monitoring needs to be performed in an experienced centre in order to minimize the occurrence of systemic adverse events or complications.<sup>235–238</sup>

*Orthopaedic surgery (blue line):* developmental paediatrician, paediatric neurologist, and rehabilitation specialist often are the initial treating physicians in children with CP. To optimize motor development it is essential to include paediatric orthopaedic surgeons into the therapeutic team as early as possible. Depending on the severity of CP frequent consultations or shared evaluations of the patient should be performed. GMFCS levels IV and V need to be monitored as early as possible for “hips at risk”.<sup>16,111</sup> The correct indication for surgery at the right time has to be established in the future with respect to GMFCS level, long-term outcome, effects and side effects on the levels of body structure and function as well as activity and participation.

### Conflicts of interest

Dr. Heinen and Dr. Berweck have received speaker's honoraria, research support and travel grants from manufacturers of the different BoNT preparations available (Allergan, Germany, IPSEN, Germany, Merz Pharmaceuticals, Germany). Dr. Schroeder reports having received lecture fees and travel grants from Allergan, Germany.

Dr. Molenaers and Mrs. Desloovere have received unrestricted educational grants, research support, speaker's honoraria and travel grants from Allergan. Dr. Hustedt and Dr. Pascual-Pascual have received speaker's honoraria, research support and travel grants from Allergan. Dr. Papavasiliou has received grants to attend scientific meetings from Allergan and Ipsen. Ms van der Pløeg has received an honorarium from Allergan for lecturing. Dr. Tedroff has chaired the Swedish Committee for Botulinum toxin A which was funded by an unrestricted grant from Allergan, and has conducted an investigator-driven randomized clinical trial where Botulinum toxin A was provided by Allergan Inc. Dr. Mall has received speaker's honoraria, research support and travel grants from manufacturers of the different BoNT preparations available (Allergan, Germany, IPSEN, Germany, Merz Pharmaceuticals, Germany). The remaining authors have received grants to attend scientific meetings from Allergan or did not state a conflict of interest.

### Acknowledgements

Florian Heinen, University of Munich, Ingeborg Krägeloh-Mann, University of Tuebingen, and Guy Molenaers, University of Leuven initiated the meeting that was held at and with the support of the University of Munich, Germany. The realisation of the meeting and the consensus table was made possible by an educational grant from Allergan. We thank Ashley Communications for the professional help in

organisational aspects of the meeting and in organisational support for preparing this manuscript.

The “CP<sup>Graph</sup> Treatment Modalities – Gross Motor Function” was developed following the innovative role of GMFM and GMFCS in the field of CP, supported by the ongoing scientific exchange with CanChild, Peter Rosenbaum and Bob Palisano, Canada, and H. Kerr Graham, Melbourne, Australia.

### Supplementary data

The graph can be downloaded from the online version, at doi: 10.1016/j.ejpn.2009.09.005.

### REFERENCES

1. Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Chaleat Valayer E, et al. European consensus table 2006 on Botulinum toxin for children with cerebral palsy. *Eur J Paediatr Neurol* 2006;**10**(5–6):215–25.
2. *Botulinumtoxin: Unerwünschte Wirkungen*. Available from: The German Federal Institute for Drugs and Medical Devices (BfArM) [http://www.bfarm.de/nn\\_424276/DE/Pharmakovigilanz/risikoinfo/2008/botulinumtoxin.html\\_nnn=true](http://www.bfarm.de/nn_424276/DE/Pharmakovigilanz/risikoinfo/2008/botulinumtoxin.html_nnn=true); 2008.
3. Follow-up to the February 8, 2008. Available from: *Early communication about an ongoing safety review of Botox and Botox cosmetic (Botulinum toxin type A) and myobloc (Botulinum toxin type B)*. Food and Drug Administration (FDA) <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm143819.htm>; 2008.
4. Himmelmann K, Hagberg G, Beckung E, Hagberg B, Uvebrant P. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995–1998. *Acta Paediatr* 2005;**94**(3):287–94.
5. Hoon A, Johnsston M. Cerebral palsy. In: Asbury A, editor. *Diseases of the nervous system, Clinical neuroscience and therapeutic principles*. Cambridge: Cambridge University Press; 2002. p. 568–80.
6. Platt MJ, Cans C, Johnson A, Surman G, Topp M, Torrioli MG, et al. Trends in cerebral palsy among infants of very low birthweight (<1500 g) or born prematurely (<32 weeks) in 16 European centres: a database study. *Lancet* 2007;**369**(9555):43–50.
7. Robertson CM, Watt MJ, Yasui Y. Changes in the prevalence of cerebral palsy for children born very prematurely within a population-based program over 30 years. *JAMA* 2007;**297**(24):2733–40.
8. Ashwal S, Russman BS, Blasco PA, Miller G, Sandler A, Shevell M, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2004;**62**(6):851–63.
9. Hart AR, Whitby EW, Griffiths PD, Smith MF. Magnetic resonance imaging and developmental outcome following preterm birth: review of current evidence. *Dev Med Child Neurol* 2008;**50**(9):655–63.
10. Robinson MN, Peake LJ, Ditchfield MR, Reid SM, Lanigan A, Reddihough DS. Magnetic resonance imaging findings in a population-based cohort of children with cerebral palsy. *Dev Med Child Neurol* 2009;**51**(1):39–45.

11. Krageloh-Mann I. Imaging of early brain injury and cortical plasticity. *Exp Neurol* 2004;190(Suppl. 1):S84–90.
12. SCPE. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). *Dev Med Child Neurol* 2000;42(12):816–24.
13. Petrucci U, Weber P, Krageloh-Mann I. The reference and trainings manual of the SCPM (Surveillance of Cerebral Palsy in Europe). *Neuropediatrics* 2004;63.
14. Palisano R, Rosenbaum PL, Walter S, Russell D, Wood E. Development and reliability of a system to classify gross motor function in children with cerebral palsy. *Dev Med Child Neurol* 1997;39(4):214–23.
15. Wood E, Rosenbaum P. The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. *Dev Med Child Neurol* 2000;42(5):292–6.
16. Hagglund G, Lauge-Pedersen H, Wagner P. Characteristics of children with hip displacement in cerebral palsy. *BMC Musculoskelet Disord* 2007;8:101.
17. Gorter JW, Rosenbaum PL, Hanna SE, Palisano RJ, Bartlett DJ, Russell DJ, et al. Limb distribution, motor impairment, and functional classification of cerebral palsy. *Dev Med Child Neurol* 2004;46(7):461–7.
18. Himmelmann K, Beckung E, Hagberg G, Uvebrant P. Gross and fine motor function and accompanying impairments in cerebral palsy. *Dev Med Child Neurol* 2006;48(6):417–23.
19. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the definition and classification of cerebral palsy April 2006. *Dev Med Child Neurol Suppl* 2007;109:8–14.
20. Kinnett D. Botulinum toxin A injections in children: technique and dosing issues. *Am J Phys Med Rehabil* 2004;83(Suppl. 10):S59–64.
21. Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized Botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. *Dev Med Child Neurol* 2006;48(3):170–5.
22. Hagglund G, Andersson S, Duppe H, Pedertsen HL, Nordmark E, Westbom L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. *J Pediatr Orthop B* 2005;14(4):268–72.
23. Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and Botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. *J Bone Joint Surg Am* 2006;88(1):161–70.
24. Lannin N, Scheinberg A, Clark K. AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after Botulinum toxin A injections. *Dev Med Child Neurol* 2006;48(6):533–9.
25. Meyer-Heim A, Ammann-Reiffer C, Schmartz A, Schaefer J, Sennhauser FH, Heinen F, et al. Improvement of walking abilities after robotic-assisted locomotion training in children with cerebral palsy. *Arch Dis Child* 2009.
26. Borggraefe I, Meyer-Heim A, Kumar A, Schaefer JS, Berweck S, Heinen F. Improved gait parameters after robotic-assisted locomotor treadmill therapy in a 6-year-old child with cerebral palsy. *Mov Disord* 2008;23(2):280–3.
27. Fasoli SE, Fragala-Pinkham M, Hughes R, Hogan N, Krebs HI, Stein J. Upper limb robotic therapy for children with hemiplegia. *Am J Phys Med Rehabil* 2008;87(11):929–36.
28. Meyer-Heim A, Borggraefe I, Ammann-Reiffer C, Berweck S, Sennhauser FH, Colombo G, et al. Feasibility of robotic-assisted locomotor training in children with central gait impairment. *Dev Med Child Neurol* 2007;49(12):900–6.
29. Phillips JP, Sullivan KJ, Burtner PA, Caprihan A, Provost B, Bernitsky-Beddingfield A. Ankle dorsiflexion fMRI in children with cerebral palsy undergoing intensive body-weight-supported treadmill training: a pilot study. *Dev Med Child Neurol* 2007;49(1):39–44.
30. Dodd KJ, Foley S. Partial body-weight-supported treadmill training can improve walking in children with cerebral palsy: a clinical controlled trial. *Dev Med Child Neurol* 2007;49(2):101–5.
31. Rodda J, Graham HK. Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. *Eur J Neurol* 2001;8(Suppl. 5):98–108.
32. Wenger D, Rang M. *The art and practice of children's orthopedics*. New York: Raven Press; 1993.
33. Heinen F, Schroeder AS, Fietzek U, Berweck S. When it comes to Botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy. *Mov Disord* 2006;21(11):2029–30.
34. Molenaers G, Eyssens M, Desloovere K, Jonkers I, De Cock P. A multilevel approach to Botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. *Eur J Neurol* 1999;6(Suppl. 4):59–62.
35. Huss K, Berweck S, Schroeder AS, Mall V, Borggraefe I, and Heinen F. Interventional-neuropaediatric spectrum of treatments with botulinum neurotoxin type A, free of complexing proteins: effective and safe application – three exemplary cases. In Abstracts of the 35th annual meeting of the Society of Neuropediatrics, Graz; 2009.
36. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. *Toxicon* 2001;39(12):1815–20.
37. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental Botulinum toxin-A injection. *Muscle Nerve* 1996;19(4):488–96.
38. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a Botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available Botulinum toxin type A (BOTOX) in healthy volunteers. *J Neural Transm* 2005;112(7):905–13.
39. WeMove, Management of Spasticity with Botulinum Toxin Type A (Botox®) – suggested pediatric Botox® dosing; 2005.
40. Shaari CM, Sanders I. Quantifying how location and dose of Botulinum toxin injections affect muscle paralysis. *Muscle Nerve* 1993;16(9):964–9.
41. Lee LR, Chuang YC, Yang BJ, Hsu MJ, Liu YH. Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. *Am J Phys Med Rehabil* 2004;83(10):766–73.
42. Bakheit AM, Severa S, Cosgrove A, Morton R, Roussounis SH, Doderlein L, et al. Safety profile and efficacy of Botulinum toxin A (Dysport) in children with muscle spasticity. *Dev Med Child Neurol* 2001;43(4):234–8.
43. Naumann M, Jankovic J. Safety of Botulinum toxin type A: a systematic review and meta-analysis. *Curr Med Res Opin* 2004;20(7):981–90.
44. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of Botulinum toxin type A following long-term use. *Eur J Neurol* 2006;13(Suppl. 4):35–40.
45. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2008;70(19):1691–8.
46. Kolaski K, Ajizian SJ, Passmore L, Pasutharnchat N, Koman LA, Smith BP. Safety profile of multilevel chemical denervation procedures using phenol or Botulinum toxin or both in a pediatric population. *Am J Phys Med Rehabil* 2008;87(7):556–66.
47. Pascual-Pascual SI, Pascual-Castroviejo I. Safety of Botulinum toxin type A in children younger than 2 years. *Eur J Paediatr Neurol* 2008.



48. Koussoulakos S. Botulinum neurotoxin: the ugly duckling. *Eur Neurol* 2009;61(6):331–42.
49. Albavera-Hernandez C, Rodriguez JM, Idrovo AJ. Safety of Botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. *Clin Rehabil* 2009;23(5):394–407.
50. Berweck S, Schroeder AS, Lee SH, Gutmann I, Schwerin A, Heinen F. Sonography in the “12Plus-concept” with Botulinum Toxin A (BOTOX) in children with cerebral palsy – accuracy, safety and secondary non-response. *Mov Disord* 2005;20(Suppl. 10):148–9.
51. Goldstein EM. Safety of high-dose Botulinum toxin type A therapy for the treatment of pediatric spasticity. *J Child Neurol* 2006;21(3):189–92.
52. Willis AW, Crowner B, Brunstrom JE, Kissel A, Racette BA. High dose Botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. *Dev Med Child Neurol* 2007;49(11):818–22.
53. Crowner BE, Racette BA. Prospective study examining remote effects of Botulinum toxin a in children with cerebral palsy. *Pediatr Neurol* 2008;39(4):253–8.
54. Howell K, Selber P, Graham HK, Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. *J Paediatr Child Health* 2007;43(6):499–501.
55. Rote-hand-brief zu Botox®, Dysport®, Vistabel®, Xeomin®. The German Federal Institute for Drugs and Medical Devices (BFARM), <http://www.bfarm.de/>; 2007.
56. Zier JL, Rivard PF, Krach LE, Wendorf HR. Effectiveness of sedation using nitrous oxide compared with enteral midazolam for Botulinum toxin A injections in children. *Dev Med Child Neurol* 2008;50(11):854–8.
57. Gubbay A, Langdon K. Effectiveness of sedation using nitrous oxide compared with enteral midazolam for Botulinum toxin A injections in children. *Dev Med Child Neurol* 2009;51(6):491–2 [author reply 492].
58. Guideline statement: management of procedure-related pain in children and adolescents paediatrics & child health division. The Royal Australasian College of Physicians Sydney Available from., <http://www.racp.edu.au/page/health-policy-and-advocacy/paediatrics-and-child-health>; 2005.
59. Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of Botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. *J Pediatr Orthop* 2005;25(3):286–91.
60. Berweck S, Feldkamp A, Francke A, Nehles J, Schwerin A, Heinen F. Sonography-guided injection of Botulinum toxin A in children with cerebral palsy. *Neuropediatrics* 2002;33(4):221–3.
61. Westhoff B, Seller K, Wild A, Jaeger M, Krauspe R. Ultrasound-guided Botulinum toxin injection technique for the iliopsoas muscle. *Dev Med Child Neurol* 2003;45(12):829–32.
62. Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy – a short review of different injection techniques. *Neurotox Res* 2006;9(2–3):189–96.
63. Beweck S, Heinen F. Cerebralparese. In: Heinen F, editor. *Blue box botulinumtoxin*. Bern: Verlag Hans Huber; 2008.
64. Fietzek U, Berweck S, Wissel J. In: *Sono's Anatomy – Focussing on Spasticity Targeting Botulinum Toxin Children & Adults*. 1st ed., vol. 1. München: Child & Brain; 2008.
65. von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with Botulinum toxin in camptocormia. *Mov Disord* 2008;23(6):889–92.
66. Yang EJ, Rha DW, Yoo JK, Park ES. Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography. *Arch Phys Med Rehabil* 2009;90(5):741–4.
67. Py AG, Zein Addeen G, Perrier Y, Carlier RY, Picard A. Evaluation of the effectiveness of Botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance. *Ann Phys Rehabil Med* 2009;52(3):215–23.
68. Rosenbaum P, Stewart D. The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy. *Semin Pediatr Neurol* 2004;11(1):5–10.
69. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, et al. A randomized study of combined Botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. *Eur J Neurol* 2001;8(Suppl. 5):75–87.
70. Desloovere K, Molenaers G, De Cat J, Pauwels P, Van Campenhout A, Ortibus E, et al. Motor function following multilevel Botulinum toxin type A treatment in children with cerebral palsy. *Dev Med Child Neurol* 2007;49(1):56–61.
71. Galli M, Cimolin V, Valente EM, Crivellini M, Ialongo T, Albertini G. Computerized gait analysis of Botulinum toxin treatment in children with cerebral palsy. *Disabil Rehabil* 2007;29(8):659–64.
72. Greenhalgh T, Taylor R. Papers that go beyond numbers (qualitative research). *BMJ* 1997;315(7110):740–3.
73. Bartlett DJ, Lucy SD. A comprehensive approach to outcomes research in rehabilitation. *Physiother Can* 2004;56:237–47.
74. Grossman J, Mackenzie FJ. The randomized controlled trial: gold standard, or merely standard? *Perspect Biol Med* 2005;48(4):516–34.
75. Palisano RJ. A collaborative model of service delivery for children with movement disorders: a framework for evidence-based decision making. *Phys Ther* 2006;86(9):1295–305.
76. Haynes RB, Devereaux PJ, Guyatt GH. Physicians' and patients' choices in evidence based practice. *BMJ* 2002;324(7350):1350.
77. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of Botulinum toxin on walking in cerebral palsy. *Arch Dis Child* 2000;83(6):481–7.
78. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. *Pediatrics* 2001;108(5):1062–71.
79. Linder-Lucht M, Kirschner J, Herrmann J, Geth K, Korinthenberg R, Berweck S, et al. Why do children with cerebral palsy discontinue therapy with Botulinum toxin A? *Dev Med Child Neurol* 2006;48(4):319–20.
80. Herrmann J, Geth K, Mall V, Bigalke H, Schulte Monting J, Linder M, et al. Clinical impact of antibody formation to Botulinum toxin A in children. *Ann Neurol* 2004;55(5):732–5.
81. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current Botulinum toxin in cervical dystonia. *Neurology* 2003;60(7):1186–8.
82. Dressler D. Botulinum toxin drugs: future developments. *J Neural Transm* 2008;115(4):575–7.
83. Darrach J, Hickman R, O'Donnell M, Vogtle L, Wiart L. AACPDm methodology to develop systematic reviews of treatment interventions 2008. Available from: <http://www.aacpdm.org/resources/systematicReviewsMethodology.pdf> [accessed July 2009].
84. Andersen GL, Irgens LM, Haagaas I, Skranes JS, Meberg AE, Vik T. Cerebral palsy in Norway: prevalence, subtypes and severity. *Eur J Paediatr Neurol* 2008;12(1):4–13.
85. Himmelman K, Beckung E, Hagberg G, Uvebrant P. Bilateral spastic cerebral palsy-prevalence through four decades,

- motor function and growth. *Eur J Paediatr Neurol* 2007;11(4): 215–22.
86. Jarvis S, Glinianaia SV, Torrioli MG, Platt MJ, Miceli M, Jouk PS, et al. Cerebral palsy and intrauterine growth in single births: European collaborative study. *Lancet* 2003; 362(9390):1106–11.
  87. Krageloh-Mann I, Hagberg G, Meisner C, Schelp B, Haas G, Eeg-Olofsson KE, et al. Bilateral spastic cerebral palsy – a comparative study between southwest Germany and western Sweden. II: epidemiology. *Dev Med Child Neurol* 1994; 36(6):473–83.
  88. Gainsborough M, Surman G, Maestri G, Colver A, Cans C. Validity and reliability of the guidelines of the surveillance of cerebral palsy in Europe for the classification of cerebral palsy. *Dev Med Child Neurol* 2008;50(11):828–31.
  89. AACPD. The definition and classification of cerebral palsy. *Dev Med Child Neurol* 2007;49(s109):1–44.
  90. Cans C, Dolk H, Platt MJ, Colver A, Prasauskiene A, Krageloh-Mann I. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. *Dev Med Child Neurol Suppl* 2007;109:35–8.
  91. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Proposed definition and classification of cerebral palsy, April 2005. *Dev Med Child Neurol* 2005;47(8): 571–6.
  92. Koman LA, Smith BP, Shilt JS. Cerebral palsy. *Lancet* 2004; 363(9421):1619–31.
  93. Krageloh-Mann I, Horber V. The role of magnetic resonance imaging in elucidating the pathogenesis of cerebral palsy: a systematic review. *Dev Med Child Neurol* 2007;49(2):144–51.
  94. Stanley FJ, Blair EM, Alberman E. *Cerebral palsies: epidemiology and causal pathways*. London: MacKeith Press; 2000.
  95. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. *Pediatrics* 2003;111(1):e89–97.
  96. Sanger TD. Pathophysiology of pediatric movement disorders. *J Child Neurol* 2003;18(Suppl. 1):S9–24.
  97. Foran JR, Steinman S, Barash I, Chambers HG, Lieber RL. Structural and mechanical alterations in spastic skeletal muscle. *Dev Med Child Neurol* 2005;47(10):713–7.
  98. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of Botulinum toxin type A in the management of cerebral palsy. *Gait Posture* 2000;11(1):67–79.
  99. Balkrishnan R, Camacho FT, Smith BP, Shilt JS, Jacks LK, Koman LA, et al. Cost impact of Botulinum toxin use in Medicaid-enrolled children with cerebral palsy. *J South Orthop Assoc* 2002;11(2):71–9.
  100. Balkrishnan R, Naughton M, Smith BP, Manuel J, Koman LA. Parent caregiver-related predictors of health care service utilization by children with cerebral palsy enrolled in Medicaid. *J Pediatr Health Care* 2002;16(2):73–8.
  101. Houltram J, Noble I, Boyd RN, Corry I, Flett P, Graham HK. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. *Eur J Neurol* 2001;8(Suppl. 5):194–202.
  102. Radensky PW, Archer JW, Dournaux SF, O'Brien CF. The estimated cost of managing focal spasticity: a physician practice patterns survey. *Neurorehabil. Neural Repair* 2001; 15(1):57–68.
  103. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. *BMJ* 2000;320(7227):79–82.
  104. Bucheler R, Schwab M, Morike K, Kalchthaler B, Mohr H, Schroder H, et al. Off label prescribing to children in primary care in Germany: retrospective cohort study. *BMJ* 2002; 324(7349):1311–2.
  105. Bakheit AM, Bower E, Cosgrove A, Fox M, Morton R, Phillips S, et al. Opinion statement on the minimal acceptable standards of healthcare in cerebral palsy. *Disability and Rehabilitation* 2001;23(10):578–82.
  106. Tilton AH, Maria BL. Consensus statement on pharmacotherapy for spasticity. *J Child Neurol* 2001;16(1):66–7.
  107. Steinlin M, Heinen F. Stellungnahme der Gesellschaft für Neuropädiatrie. Therapeutischer Wert von Botulinumtoxin bei der Behandlung von Bewegungsstörungen mit Spastizität im Kindesalter. *Neuropädiatrie in Klinik und Praxis* 2003;4:171.
  108. Liptak GS, Accardo PJ. Health and social outcomes of children with cerebral palsy. *J Pediatr* 2004;145(Suppl. 2): S36–41.
  109. Ackman JD, Russman BS, Thomas SS, Buckon CE, Sussman MD, Masso P, et al. Comparing Botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. *Dev Med Child Neurol* 2005;47(9):620–7.
  110. Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, et al. Analgesic effects of Botulinum toxin A: a randomized, placebo-controlled clinical trial. *Dev Med Child Neurol* 2000; 42(2):116–21.
  111. Graham HK, Boyd R, Carlin JB, Dobson F, Lowe K, Nattrass G, et al. Does Botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and “hips at risk”? A randomized, controlled trial. *J Bone Joint Surg Am* 2008;90(1):23–33.
  112. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. *J Pediatr Orthop* 1998;18(3):304–11.
  113. Kay RM, Rethlefsen SA, Fern-Buneo A, Wren TA, Skaggs DL. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. *J Bone Joint Surg Am* 2004; 86-A(11):2377–84.
  114. Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. *Dev Med Child Neurol* 2006;48(1):10–3.
  115. Reddihough DS, King JA, Coleman GJ, Fosang A, McCoy AT, Thomason P, et al. Functional outcome of Botulinum toxin A injections to the lower limbs in cerebral palsy. *Dev Med Child Neurol* 2002;44(12):820–7.
  116. Russo RN, Crotty M, Miller MD, Murchland S, Flett P, Haan E. Upper-limb Botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. *Pediatrics* 2007;119(5):e1149–58.
  117. Speth LA, Leffers P, Janssen-Potten YJ, Vles JS. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. *Dev Med Child Neurol* 2005;47(7):468–73.
  118. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al. The combined effect of lower-limb multilevel Botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. *Arch Phys Med Rehabil* 2006;87(12):1551–8.
  119. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al. Effect of multilevel Botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy. *Pediatr Neurol* 2007;36(1):30–9.
  120. Wallen M, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular Botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. *Arch Phys Med Rehabil* 2007; 88(1):1–10.
  121. Olesch CA, Greaves S, Imms C, Reid SM, Graham HK. Repeat Botulinum toxin-A injections in the upper limb of children

- with hemiplegia: a randomized controlled trial. *Dev Med Child Neurol* 2009.
122. Wallen MA, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular Botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. *Arch Phys Med Rehabil* 2004;**85**(2):192–200.
  123. Autti-Ramo I, Anttila H, Makela M. Are current practices in the treatment of children with cerebral palsy research-based? *Dev Med Child Neurol* 2007;**49**(2):155–6.
  124. Wright FV, Rosenbaum PL, Goldsmith CH, Law M, Fehlings DL. How do changes in body functions and structures, activity, and participation relate in children with cerebral palsy? *Dev Med Child Neurol* 2008;**50**(4):283–9.
  125. Tilton AH. Therapeutic interventions for tone abnormalities in cerebral palsy. *NeuroRx* 2006;**3**(2):217–24.
  126. Papavasiliou AS. Management of motor problems in cerebral palsy: A critical update for the clinician. *Eur J Paediatr Neurol*; 2008.
  127. Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P. Pharmacotherapy of spasticity in children with cerebral palsy. *Pediatr Neurol* 2006;**34**(1):1–6.
  128. Leach J. Children undergoing treatment with Botulinum toxin: the role of the physical therapist. *Muscle Nerve* 1997;**6**:194–207.
  129. Dumas HM, O'Neil ME, Fragala MA. Expert consensus on physical therapist intervention after Botulinum toxin A Injection for children with cerebral palsy. *Pediatr Phys Ther* 2001;**13**(3):122–32.
  130. Mayston M. Evidence-based physical therapy for the management of children with cerebral palsy. *Dev Med Child Neurol* 2005;**47**(12):795.
  131. Hoare BJ, Imms C. Upper-limb injections of Botulinum toxin-A in children with cerebral palsy: a critical review of the literature and clinical implications for occupational therapists. *Am J Occup Ther* 2004;**58**(4):389–97.
  132. Blackmore AM, Boettcher-Hunt E, Jordan M, Chan MD. A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPD. *Dev Med Child Neurol* 2007;**49**(10):781–90.
  133. Hoare BJ, Wasiak J, Imms C, Carey L. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy. *Cochrane Database Syst Rev* 2007;**2**:CD004149.
  134. Carr LJ, Cosgrove AP, Gringras P, Neville BG. Position paper on the use of Botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party. *Arch Dis Child* 1998;**79**(3):271–3.
  135. Anttila H, Autti-Ramo I, Suoranta J, Makela M, Malmivaara A. Effectiveness of physical therapy interventions for children with cerebral palsy: a systematic review. *BMC Pediatr* 2008;**8**:14.
  136. Autti-Ramo I, Suoranta J, Anttila H, Malmivaara A, Makela M. Effectiveness of upper and lower limb casting and orthoses in children with cerebral palsy: an overview of review articles. *Am J Phys Med Rehabil* 2006;**85**(1):89–103.
  137. Gormley Jr ME, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. *Eur J Neurol* 2001;**8**(Suppl. 5):127–35.
  138. Koman LA, Mooney JF, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. *J Pediatr Orthop* 2000;**20**(1):108–15.
  139. Bjornson K, Hays R, Graubert C, Price R, Won F, McLaughlin JF, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. *Pediatrics* 2007;**120**(1):49–58.
  140. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. *J Paediatr Child Health* 1999;**35**(1):71–7.
  141. Polak F, Morton R, Ward C, Wallace WA, Doderlein L, Siebel A. Double-blind comparison study of two doses of Botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. *Dev Med Child Neurol* 2002;**44**(8):551–5.
  142. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. *Gait Posture* 1999;**10**(1):1–9.
  143. Kang BS, Bang MS, Jung SH. Effects of Botulinum toxin A therapy with electrical stimulation on spastic calf muscles in children with cerebral palsy. *Am J Phys Med Rehabil* 2007.
  144. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of Botulinum toxin A on gastrocnemius length: magnitude and duration of response. *Dev Med Child Neurol* 1999;**41**(4):226–32.
  145. Satila HK, Pietikainen T, Lehtonen-Raty P, Koivikko M, Autti-Ramo I. Treatment of spastic equinus gait with Botulinum toxin A: does dose matter? Analysis of a clinical cohort. *Neuropediatrics* 2006;**37**(6):344–9.
  146. Chambers HG. Treatment of functional limitations at the knee in ambulatory children with cerebral palsy. *Eur J Neurol* 2001;**8**(Suppl. 5):59–74.
  147. Boyd RN, Dobson F, Parrott J, Love S, Oates J, Larson A, et al. The effect of Botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. *Eur J Neurol* 2001;**8**(Suppl. 5):109–19.
  148. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. *Dev Med Child Neurol* 1997;**39**(3):185–93.
  149. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy [see comments]. *J Pediatr* 2000;**137**(3):331–7.
  150. Satila H, Kotamaki A, Koivikko M, Autti-Ramo I. Low- and high-dose Botulinum toxin A treatment: a retrospective analysis. *Pediatr Neurol* 2006;**34**(4):285–90.
  151. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, et al. Management of spasticity associated pain with Botulinum toxin A. *J Pain Symptom Manage* 2000;**20**(1):44–9.
  152. Dressler D. Electromyographic evaluation of cervical dystonia for planning of Botulinum toxin therapy. *Eur J Neurol* 2000;**7**(6):713–8.
  153. Flett PJ. Rehabilitation of spasticity and related problems in childhood cerebral palsy. *J Paediatr Child Health* 2003;**39**(1):6–14.
  154. Ward AB, Molenaers G, Colosimo C, Berardelli A. Clinical value of Botulinum toxin in neurological indications. *Eur J Neurol* 2006;**13**(Suppl. 4):20–6.
  155. King S, Teplicky R, King G, Rosenbaum P. Family-centered service for children with cerebral palsy and their families: a review of the literature. *Semin Pediatr Neurol* 2004;**11**(1):78–86.
  156. Berweck S, Kerr HG, Heinen F. Chapter 11, Spasticity in children. In: Moore P, Naumann M, editors. *Handbook of Botulinum toxin treatment*. 2nd ed. Oxford, Victoria, Berlin: Blackwell Science Ltd; 2003. p. 272–305.
  157. Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. *J Child Neurol* 2003;**18**(Suppl. 1):S50–66.
  158. Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. *Cochrane Database Syst Rev* 2004;**4**:CD003469.
  159. Ade-Hall R, Moore A. A systematic review of controlled trials of the use of Botulinum toxin type A for the treatment of lower limb spasticity in cerebral palsy. *Cochrane Library* 2003; 1:1–19.

160. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. *Drugs* 2007;**67**(5):669–83.
161. Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. *Clin Neuropharmacol* 2007;**30**(2):86–94.
162. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. *Nature* 1993;**365**(6442):160–3.
163. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A. *Science* 2006;**312**(5773):592–6.
164. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. *FEBS Lett* 2006;**580**(8):2011–4.
165. Schmid MF, Robinson JP, DasGupta BR. Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles. *Nature* 1993;**364**(6440):827–30.
166. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Lauro P, DasGupta BR, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]. *Nature* 1992;**359**(6398):832–5.
167. Molenaers G, Schorkhuber V, Fagard K, Van Campenhout A, De Cat J, Pauwels P, et al. Long-term use of Botulinum toxin type A in children with cerebral palsy: treatment consistency. *Eur J Paediatr Neurol* 2008.
168. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. *Dev Med Child Neurol* 2002;**44**(10):666–75.
169. Hu GC, Chuang YC, Liu JP, Chien KL, Chen YM, Chen YF. Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes. *Clin Rehabil* 2009;**23**(1):64–71.
170. Sanger TD, Kukke SN, Sherman-Levine S. Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: an open-label, dose-escalation pilot study. *J Child Neurol* 2007;**22**(1):116–22.
171. Schwerin A, Berweck S, Fietzek UM, Heinen F. Botulinum toxin B treatment in children with spastic movement disorders: a pilot study. *Pediatr Neurol* 2004;**31**(2):109–13.
172. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Muller J, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of “high-dose” versus “low-dose” treatment. *Neuropediatrics* 1999;**30**(3):120–4.
173. Valtorta F, Arslan G. The pharmacology of Botulinum toxin [review]. *Pharmacol.Res.* 1993;**27**(1):33–44.
174. Gracies JM. Physiological effects of Botulinum toxin in spasticity. *Mov Disord* 2004;**19**(Suppl. 8):S120–8.
175. Jefferson RJ. Botulinum toxin in the management of cerebral palsy. *Dev Med Child Neurol* 2004;**46**(7):491–9.
176. Mohamed K, Moore AP, Rosenbloom L. Adverse events following repeated injections with Botulinum toxin A in children with spasticity. *Dev Med Child Neurol* 2001;**43**:791–2.
177. Rossi RP, Strax TE, Di Rocco A. Severe Dysphagia after Botulinum toxin B injection to the lower limbs and lumbar paraspinal muscles. *Am J Phys Med Rehabil* 2006;**85**(12):1011–3.
178. Berweck S, Schroeder AS, Lee SH, Bigalke H, Heinen F. Secondary non-response due to antibody formation in a child after three injections of Botulinum toxin B into the salivary glands. *Dev Med Child Neurol* 2007;**49**(1):62–4.
179. Moore AP, Ade-Hall RA, McDowell M, Rosenbloom L, Mohamed K, Walsh H. Children with cerebral palsy tolerate repeated Botulinum toxin injection sessions without general anaesthetic. *Movement Disorders* 2001;**16**(2):381.
180. Frampton A, Browne GJ, Lam LT, Cooper MG, Lane LG. Nurse administered relative analgesia using high concentration nitrous oxide to facilitate minor procedures in children in an emergency department. *Emerg Med J* 2003;**20**(5):410–3.
181. Kanagasundaram SA, Lane LJ, Cavalletto BP, Keneally JP, Cooper MG. Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures. *Arch Dis Child* 2001;**84**(6):492–5.
182. Barbano RL. Needle EMG guidance for injection of Botulinum toxin. Needle EMG guidance is useful. *Muscle Nerve* 2001;**24**(11):1567–8.
183. Jankovic J. Needle EMG guidance for injection of Botulinum toxin. Needle EMG guidance is rarely required. *Muscle Nerve* 2001;**24**(11):1568–70.
184. Kennedy RM, Luhmann JD, Luhmann SJ. Emergency department management of pain and anxiety related to orthopedic fracture care: a guide to analgesic techniques and procedural sedation in children. *Paediatr Drugs* 2004;**6**(1):11–31.
185. Allington NJ, Leroy N, Doneux C. Ankle joint range of motion measurements in spastic cerebral palsy children: intraobserver and interobserver reliability and reproducibility of goniometry and visual estimation. *J Pediatr Orthop B* 2002;**11**(3):236–9.
186. McDowell BC, Hewitt V, Nurse A, Weston T, Baker R. The variability of goniometric measurements in ambulatory children with spastic cerebral palsy. *Gait Posture* 2000;**12**(2):114–21.
187. Damiano DL, Quinlivan JM, Owen BF, Payne P, Nelson KC, Abel MF. What does the Ashworth scale really measure and are instrumented measures more valid and precise? *Dev Med Child Neurol* 2002;**44**(2):112–8.
188. Scholtes VA, Becher JG, Beelen A, Lankhorst GJ. Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments. *Dev Med Child Neurol* 2006;**48**(1):64–73.
189. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of Botulinum toxin type A for the management of children with cerebral palsy. *European Journal of Neurology* 1999;**6**(Suppl. 4):23–35.
190. Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP, et al. Validation of a model of gross motor function for children with cerebral palsy. *Phys Ther* 2000;**80**(10):974–85.
191. Beckung E, Carlsson G, Carlsdotter S, Uvebrant P. The natural history of gross motor development in children with cerebral palsy aged 1 to 15 years. *Dev Med Child Neurol* 2007;**49**(10):751–6.
192. Cusick A, McIntyre S, Novak I, Lannin N, Lowe K. A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. *Pediatr Rehabil* 2006;**9**(2):149–57.
193. Palisano RJ. Validity of goal attainment scaling in infants with motor delays. *Phys Ther* 1993;**73**(10):651–8.
194. Steenbeek D, Ketelaar M, Galama K, Gorter JW. Goal attainment scaling in paediatric rehabilitation: a critical review of the literature. *Dev Med Child Neurol* 2007;**49**(7):550–6.
195. Kerr Graham H, Selber P. Musculoskeletal aspects of cerebral palsy. *J Bone Joint Surg Br* 2003;**85**(2):157–66.
196. Maathuis KG, van der Schans CP, van Iperen A, Rietman HS, Geertzen JH. Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing scale. *J Pediatr Orthop* 2005;**25**(3):268–72.
197. Read HS, Hazlewood ME, Hillman SJ, Prescott RJ, Robb JE. Edinburgh visual gait score for use in cerebral palsy. *J Pediatr Orthop* 2003;**23**(3):296–301.

198. Mackey AH, Lobb GL, Walt SE, Stott NS. Reliability and validity of the Observational Gait Scale in children with spastic diplegia. *Dev Med Child Neurol* 2003;**45**(1):4–11.
199. Feldman AB, Haley SM, Coryell J. Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. *Phys Ther* 1990;**70**(10):602–10.
200. Beckung E, Hagberg G. Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. *Dev Med Child Neurol* 2002;**44**(5):309–16.
201. Eliasson AC, Krumlinde-Sundholm L, Rosblad B, Beckung E, Arner M, Ohrvall AM, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. *Dev Med Child Neurol* 2006;**48**(7):549–54.
202. Morris C, Kurinczuk JJ, Fitzpatrick R, Rosenbaum PL. Reliability of the manual ability classification system for children with cerebral palsy. *Dev Med Child Neurol* 2006;**48**(12):950–3.
203. Krumlinde-Sundholm L, Holmefur M, Kottorp A, Eliasson AC. The Assisting Hand Assessment: current evidence of validity, reliability, and responsiveness to change. *Dev Med Child Neurol* 2007;**49**(4):259–64.
204. Johnson LM, Randall MJ, Reddihough DS, Oke LE, Byrt TA, Bach TM. Development of a clinical assessment of quality of movement for unilateral upper-limb function. *Dev Med Child Neurol* 1994;**36**(11):965–73.
205. Randall M, Carlin JB, Chondros P, Reddihough D. Reliability of the Melbourne assessment of unilateral upper limb function. *Dev Med Child Neurol* 2001;**43**(11):761–7.
206. Bourke-Taylor H. Melbourne Assessment of Unilateral Upper Limb Function: construct validity and correlation with the Pediatric Evaluation of Disability Inventory. *Dev Med Child Neurol* 2003;**45**(2):92–6.
207. Balkrishnan R, Manuel JC, Smith BP, Camacho FT, Koman LA. Longitudinal examination of health outcomes associated with Botulinum toxin use in children with cerebral palsy. *J Surg Orthop Adv* 2004;**13**(2):76–80.
208. Narayanan UG, Fehlings D, Weir S, Knights S, Kiran S, Campbell K. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCCHILD). *Dev Med Child Neurol* 2006;**48**(10):804–12.
209. Beckung E, White-Koning M, Marcelli M, McManus V, Michelsen S, Parkes J, et al. Health status of children with cerebral palsy living in Europe: a multi-centre study. *Child Care Health Dev* 2008;**34**(6):806–14.
210. Davis E, Shelly A, Waters E, Davern M. Measuring the quality of life of children with cerebral palsy: comparing the conceptual differences and psychometric properties of three instruments. *Dev Med Child Neurol*; 2009.
211. Paolicelli PB. Use of Botulinum toxin type A in walking disorders of children with cerebral palsy. *Eur Medicophys* 2001;**37**:83–92.
212. Steenbeek D, Meester-Delver A, Becher JG, Lankhorst GJ. The effect of Botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. *Clin Rehabil* 2005;**19**(3):274–82.
213. Lowe K, Novak I, Cusick A. Repeat injection of Botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy. *Dev Med Child Neurol* 2007;**49**(11):823–9.
214. Zurcher AW, Molenaers G, Desloovere K, Fabry G. Kinematic and kinetic evaluation of the ankle after intramuscular injection of Botulinum toxin A in children with cerebral palsy. *Acta Orthop.Belg* 2001;**67**(5):475–80.
215. Mackey AH, Miller F, Walt SE, Waugh MC, Stott NS. Use of three-dimensional kinematic analysis following upper limb Botulinum toxin A for children with hemiplegia. *Eur J Neurol* 2008;**15**(11):1191–8.
216. Vles GF, de Louw AJ, Speth LA, van Rhijn LW, Janssen-Potten YJ, Hendriksen JG, et al. Visual Analogue Scale to score the effects of Botulinum toxin A treatment in children with cerebral palsy in daily clinical practice. *Eur J Paediatr Neurol* 2008;**12**(3):231–8.
217. Bower E, McLellan DL. Evaluating therapy in cerebral palsy. *Child Care Health Dev* 1994;**20**(6):409–19.
218. Majnemer A, Mazer B. New directions in the outcome evaluation of children with cerebral palsy. *Semin Pediatr Neurol* 2004;**11**(1):11–7.
219. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? *Curr Opin Neurol* 2001;**14**(6):771–6.
220. Fosang AL, Galea MP, McCoy AT, Reddihough DS, Story I. Measures of muscle and joint performance in the lower limb of children with cerebral palsy. *Dev Med Child Neurol* 2003;**45**(10):664–70.
221. Ketelaar M, Vermeer A, Helders P. Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. *Clin Rehabil* 1998;**12**:369–80.
222. Biering-Sorensen F, Nielsen JB, Klinge K. Spasticity-assessment: a review. *Spinal Cord* 2006;**44**(12):708–22.
223. Harvey A, Robin J, Morris ME, Graham HK, Baker R. A systematic review of measures of activity limitation for children with cerebral palsy. *Dev Med Child Neurol* 2008;**50**(3):190–8.
224. Metaxiotis D, Siebel A, Doederlein L. Repeated Botulinum toxin A injections in the treatment of spastic equinus foot. *Clin Orthop* 2002;**394**:177–85.
225. Hawamdeh ZM, Ibrahim AI, Al-Qudah AA. Long-term effect of Botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy. *Eura Medicophys* 2007;**43**(3):311–8.
226. Schroeder AS, Ertl-Wagner B, Britsch S, Schroder JM, Nikolin S, Weis J, et al. Muscle biopsy substantiates long-term MRI alterations one year after a single dose of Botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers. *Mov Disord* 2009;**24**(10):1494–503.
227. Lowing K, Bexelius A, Brogren Carlberg E. Activity focused and goal directed therapy for children with cerebral palsy - Do goals make a difference? *Disabil Rehabil* 2009:1–9.
228. Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. *Jama* 2002;**288**(11):1357–63.
229. Damiano D. Physiotherapy management of CP: moving beyond philosophies. In: Scrutton D, Damiano D, Mayston M, editors. *Management of the motor disorders of the child with CP*. London: Mac Keith Press; 2004.
230. Eliasson AC. Improving the use of hands in daily activities: aspects of the treatment of children with cerebral palsy. *Phys Occup Ther Pediatr* 2005;**25**(3):37–60.
231. Pin T, Dyke P, Chan M. The effectiveness of passive stretching in children with cerebral palsy. *Dev Med Child Neurol* 2006;**48**(10):855–62.
232. Davids JR, Rowan F, Davis RB. Indications for orthoses to improve gait in children with cerebral palsy. *J Am Acad Orthop Surg* 2007;**15**(3):178–88.
233. Edgar TS. Oral pharmacotherapy of childhood movement disorders. *J Child Neurol* 2003;**18**(Suppl. 1):S40–9.
234. O'Flaherty S, Waugh MC. Pharmacologic management of the spastic and dystonic upper limb in children with cerebral palsy. *Hand Clin* 2003;**19**(4):585–9.
235. Buonaguro V, Scelsa B, Curci D, Monforte S, Iuorno T, Motta F. Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. *Pediatr Neurol* 2005;**33**(2):110–3.

236. de Lissovoy G, Matza LS, Green H, Werner M, Edgar T. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. *J Child Neurol* 2007;**22**(1):49–59.
237. Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Sleypen FA, Vles JS. Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study. *Dev Med Child Neurol* 2007;**49**(9):654–9.
238. Kolaski K, Logan LR. A review of the complications of intrathecal baclofen in patients with cerebral palsy. *NeuroRehabilitation* 2007;**22**(5):383–95.